Amneal Pharmaceuticals Inc. (AMRX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (36.9% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $20.44 (-4.97% 1D, market cap $7.49B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AMRX ranks #67 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRX carries a Roarable B- (71/100 RQD), trailing P/E of 103.2x, gross margin of 36.9%, and ROIC of 14.1%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).
Per AMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723128), Amneal Pharmaceuticals Inc. generated $3.02B in revenue (+8.0% YoY), $72.1M in net income, and $269.9M in free cash flow against $3.68B in total assets and $2.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.8% realized swing band)
Altman Z-Score 3.83 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
Even with a 71/100 (B-) score, AMRX faces multiple-compression risk if 103.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 103x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 34.4% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.33) or 200D SMA ($15.86) invalidates the momentum regime and cuts Target Base ($21.64) toward Bear Floor ($16.76).
Amneal Pharmaceuticals Inc. (AMRX) dropped -4.97% to $20.44, trading at 89% of its 52-week range ($10.68 – $21.68). High-quality cash engine (36.9% gross margin, 14% return on capital) with steady institutional support.
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Zacks Investment Research report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AMRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AMRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Amneal Pharmaceuticals Inc. (AMRX) ranks #67 by composite RQD confidence (71/100, grade B-) and #130 by equity capitalization ($7.49B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with AMRX at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMRX
ACTIVE
Amneal Pharmaceuticals Inc. | B- | 71/100 | 103.2x | 36.9% | 14.1% | -4.97% | $7.49B | Benchmark Subject |
| ABVX Abivax SA | D+ | 54/100 | 32.8x | — | 9.9% | -1.94% | $7.56B | /abvx-vs-amrx → |
| AXSM Axsome Therapeutics Inc. | D- | 35/100 | — | — | -21.9% | -5.83% | $7.57B | /axsm-vs-amrx → |
| ALKS Alkermes plc | B+ | 78/100 | 31.5x | 86.7% | 14.0% | -0.99% | $7.61B | /alks-vs-amrx → |
| KNSA Kiniksa Pharmaceuticals International plc (Class A) | B- | 71/100 | 129.9x | 88.5% | 9.9% | -1.56% | $7.25B | /knsa-vs-amrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported GAAP revenue of $3.02B (+8.0% vs. FY2024 revenue of $2.79B , and +26.1% cumulative change since FY2023) , GAAP net income of $72.1M, operating cash flow of $340.0M, and free cash flow of $269.9M (+11.0% YoY). On the balance sheet, AMRX closed FY2025 with $3.68B in total assets against $2.57B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.02B | $72.1M | $340.0M | $269.9M | $3.68B | $2.57B |
| FY2024 (FY) | 2024-12-31 | $2.79B | -$116.9M | $295.1M | $243.2M | $3.50B | $2.16B |
| FY2023 (FY) | 2023-12-31 | $2.39B | -$84.0M | $345.6M | $237.9M | $4.09B | $957.0M |
As of 2026-11-03, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $20.44 (-4.97% 1D, market cap $7.49B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AMRX ranks #67 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRX carries a Roarable B- (71/100 RQD), trailing P/E of 103.2x, gross margin of 36.9%, and ROIC of 14.1%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).
Per AMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723128), Amneal Pharmaceuticals Inc. generated $3.02B in revenue (+8.0% YoY), $72.1M in net income, and $269.9M in free cash flow against $3.68B in total assets and $2.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
AMRX last traded at $20.44 (-4.97% on volume of 5,019,747 shares), positioning the stock +5.74% above its 50-day simple moving average ($19.33) and +28.88% above its 200-day simple moving average ($15.86). Across its 52-week range of $10.68 to $21.68, AMRX sits at the 88.7% percentile with a 14-day RSI of 66.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($19.25 to $21.63).
Amneal Pharmaceuticals Inc. (AMRX) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $20.44 (-4.97% 1D, market capitalization $7.49B).
Amneal Pharmaceuticals Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Specific product lines, customer base, and revenue model details are — The company's scale is reflected in its $7.44B market capitalization and reported FY 2025 revenue of $3.02B, .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported $3.02B in annual revenue (up from $2.79B in FY2024, +8.0% YoY) and $72.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.39B revenue, -$84.0M net income) through FY2025, AMRX scaled operating cash flow to $340.0M and free cash flow to $269.9M, backed by $3.68B in total assets against $2.57B in total debt.
No upstream or downstream dependencies, sector correlations, or bottleneck links are recorded (supply chain: NONE; butterfly links: empty). Specific upstream supplier and downstream customer relationships are — A prospective investor should monitor the Q3 earnings release and any valuation-driven volatility identified in the news feed, as these are the nearest-term signals in the available data.
Real-time company headlines, analyst actions, and sector developments for Amneal Pharmaceuticals Inc. (AMRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Zacks Investment Research report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Amneal Pharmaceuticals Inc. (AMRX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on AMRX here at $21.51: Institutional whale-flow (18/20) and a strong forensic balance sheet (Altman Z 3.83, Piotroski F 9/9) support the B-grade Buy rating.. Compare AMRX's 13.1% operating margin and 14.1% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $20.43 are getting bought.
@ForensicBear Shorting a 17/20 institutional whale-flow stock at $21.51 is dangerous when funds are rotating into Health Care.
Trailing P/E of 103.2 against a 2.4% net margin and $0.21 EPS leaves the stock priced for growth that the reported earnings do not yet show.. Look at the math on AMRX: paying 103.2x trailing P/E for 14.1% ROIC and 13.1% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $18.93 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: